News

March 14, 2016

ViveBio and Butantan Institute Enter into a Collaboration Agreement for Research in Sample Stabilization Technology to Support Phase III Dengue Vaccine Studies

click here to view the press release

January 11, 2016

COMBINED TECHNOLGIES OF VIVEBIO AND ZEPTOMETRIX FEATURED IN STUDY PRESENTED AT HEP DART 2015

Dried and Stabilized Serological Controls for Hepatitis B, Hepatitis C and HIV Assays Support Quality Assurance Schemes Without Cold Chain Logistics. (click here to view the press release)

December 8, 2015

Two Posters Featuring ViveBio's Dried Matrix Technology Presented at HEP DART 2015

Two posters featuring ViveBio’s dried matrix technology were presented at HEP DART 2015 held December 4-8, 2015 in Wailea, Hawaii. A poster entitled, Dried Thermostable Technology for Deployment of Hepatitis B, Hepatitis C and HIV Serological Assay Controls & Calibrators, summarized the use of the ViveST dried matrix with Zeptometrix serological assay controls and calibrators. A second poster entitled, Proof of Concept: Novel Plasma Separation Cards for HCV/HIV Quantitation, describes the functionality and performance of a prototype plasma separation card that allows plasma to be collected via a finger prick: Dried Thermostable Technology for Deployment of Hepatitis B, Hepatitis C and HIV Serological Assay Controls & Calibrators and Proof of Concept: Novel Plasma Separation Cards for HCV/HIV Quantitation

November 6, 2015

A Poster Featuring ViveBio’s Transport Device, ViveST®, Presented at Kidney Week 2015

A poster featuring ViveBio’s dried, shelf-stable technology ViveST® was presented at the Kidney Week 2015 meeting held November 3-8, 2015 in San Diego, California. The poster entitled, Detection of Inflammatory Biomarkers in Urine Using a Dried, Shelf Stable Transport Device, ViveST™, summarized a study transporting urine in a dried state for use with a non-invasive kidney transplant rejection biomarker, eliminating the need for cold chain transport and storage of urine specimen. View the poster here.

November 5, 2015

Three Posters Featuring ViveBio’s Dry-Transport Technology Were Presented at AMP 2015

Three posters featuring ViveBio’s dry-transport technology were presented at the Association for Molecular Pathology meeting held November 5-8, 2015 in Austin, Texas. The posters were entitled, Evaluation of Stability of Reference Materials for Infectious Disease Testing at Elevated Temperatures in Liquid and Dry States, Dry-Transport Technology for Molecular Diagnostic Controls and, Novel Plasma Separation Cards for Collection in Resource-Limited Settings (click each title to view poster).

July 27, 2015

SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry

Combined Technologies Offer IVD Developers New Tools for Collection, Stabilization and QC. (click here to view the press release)

April 29, 2015

A Poster Featuring ViveST™ Presented at 31st Annual Clinical Virology Symposium, April 26-29, 2015, Daytona Beach, FL

A poster featuring ViveST™ was presented by Anita McClernon of bioMONTR®, an independent research laboratory located in Research Triangle Park, North Carolina, during the 31st Annual Clinical Virology Symposium held April 26-29, 2015 in Daytona Beach, Florida. The poster entitled, Room Temperature Stable, Dry-Transport Technology for Molecular Diagnostic Controls, evaluated the use of ViveST™ for storage and shipment of molecular diagnostics controls. The study concluded that "ViveST can be used as storage and shipping method for molecular controls in dried, stable format that eliminates the need for cold chain storage." (click here to view the poster)

March 1, 2015

A Poster Featuring ViveBio’s ViveST Presented at the 2015 International HIV Drug Resistance Workshop

A poster featuring ViveST® was presented at the 2015 International HIV Drug Resistance Workshop held February 21-22, 2015 in Seattle, Washington. The poster entitled, High HIV Drug Resistance in Naïve, Recently Diagnosed Patients in Gondar, Ethiopia, evaluated HIV drug resistance in drug-naïve patients 10 years after being treated with combination anti-retroviral therapy (cART)... (click here to view the poster release)

February 10, 2015

VIVEBIO, LLC ENTERS WORLDWIDE EXCLUSIVE LICENSING AGREEMENT WITH RENOVAR INC. FOR NOVEL URINE BASED BIOMARKER TECHNOLOGIES COVERING KIDNEY DISEASE AND TRANSPLANT MONITORING

Noninvasive Technology Can Be Used To Monitor Kidney Transplant Patients For Rejection (click here to view the press release)

December 10, 2014

A Poster Featuring ViveBio’s Plasma Separation Card Prototype Presented at HIV DART 2014

A poster featuring ViveBio’s new plasma separation card was presented at the HIV DART 2014 meeting held December 9-12, 2014 in Miami, Florida. The poster entitled, Proof of Concept: Plasma Separation Cards for Collection in Resource-Limited Settings, summarized a proof of concept study that tested the functionality and performance of this novel device. (View the Poster Here)

November 15, 2014

A Poster Featuring ViveST™ Presented at AMP 2014 Annual Meeting

A poster featuring ViveST™ was presented by Daniel McClernon of bioMONTR®, an independent research laboratory located in Research Triangle Park, North Carolina, during the 2014 Annual Meeting of the Association for Molecular Pathology held November 12-15, 2014 in National Harbor, Maryland. The poster entitled, Ambient Temperature Shipping and Storage for Molecular Infectious Disease Testing: ViveST®, summarized results of a study that evaluated the stability of HIV-1 plasma samples shipped and stored on ViveST®. View the Poster Here.

November 5, 2014

A Poster Featuring ViveST™ Presented at 63rd Annual Meeting of ASTMH

A poster featuring ViveST™ was presented by the Naval Medical Research Center during the 63rd Annual Meeting of the American Society of Tropical Medicine and Hygiene held November 2-16, 2014 in New Orleans, Louisiana. The poster entitled, Nucleic Acid and Antibody Integrity in Clinical Samples on Dried Blood Stabilization Products During Ambient Temperature Shipment, summarized results of a study that tested down-selected products in the field by using them to ship clinical dengue-positive whole blood samples from Iquitos to Lima, Peru for analysis. View the Poster Here.

August 26, 2014
PRESS RELEASE

ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products New Partnership Expands Access to Cost-Saving Biological Specimen Transport System

Alpharetta, Georgia, August 26, 2014 – ViveBio, LLC a leading provider of products for ambient biological sample collection, stabilization and transportation, announced today that it has signed a distribution agreement with Laboratory Procurement Services, LLC (LPS) of Knoxville, Tennessee to distribute the ViveST line of products in the United States. ViveST is the first of a new class of ambient temperature dried biological specimen transport systems. The technology enables easy, reliable and cost effective transport of specimens without the need for traditional cold chain logistics.

"We believe ViveST has the potential to significantly change the way biological samples are collected, stored and transported throughout the world," said Timothy Murray, President of ViveBio. "The agreement with LPS further expands ViveBio’s reach into a wide range of laboratories throughout the U.S."

"We’re excited to add ViveST to the LPS product portfolio," said Max Tyrrell, CEO of LPS. "We see this as a great way to help our customers reduce their sample shipment costs as they face continual pricing pressure."

ViveST is CE marked for sale in Europe and ANVISA registered in Brazil.

About ViveBio, LLC

ViveBio, LLC is a privately held biotechnology company focused on providing high quality yet cost-effective solutions for dried biological specimen transportation and storage. ViveBio’s mission is to expand access to healthcare and extend life through these cost effective solutions and other breakthrough technologies. The company’s manufacturing and corporate office are located in Alpharetta, Georgia. For more information regarding ViveST and recent scientific publications and posters, please visit the ViveBio website at www.vivebio.com.

About Laboratory Procurement Services, LLC

Lab Procurement Services, LLC is a privately held biotechnology marketing and procurement services company specializing in the medical research and industrial laboratory market sectors. LPS mission is to help lower the costs of acquisition for its clients and to provide marketing and support services to biotechnology companies with unique, breakthrough technologies. The company’s corporate offices and secure data center are located in Knoxville, Tennessee. For more information regarding Lab Procurement Services, please visit the LPS website at www.labproservices.com.

ViveBio, LLC
Corporate Contact:
Brad Nelson: 1-877-814-7004
Chief Administrative Officer
nelson@vivebio.com

Laboratory Procurement Services, LLC
Corporate Contact:
Jon Bird: 1-865-622-5322
Executive Vice President

April 28, 2014
A Poster Featuring ViveST™ Presented at 30th Annual Clinical Virology Symposium, April 27-30, 2014, Daytona Beach, Florida.

A poster featuring ViveST™ was presented by Daniel McClernon of bioMONTR®, an independent research laboratory located in Research Triangle Park, North Carolina, during the 30th Annual Clinical Virology Symposium held April 27-30, 2014 in Daytona Beach, Florida. The poster entitled Detection of Low Level HCV RNA in Room Temperature Stored Samples Using ViveST™, a Transformational Storage and Transport Device, evaluated the storage of low titer HCV plasma using ViveST™ in combination with Abbott RealTime HCV assay. The studies presented demonstrate ViveST’s utility for storage of low titer HCV plasma and it’s unique reproducibility profile for monitoring HCV viral load during drug therapy.

Click Here to View the Poster

About ViveBio, LLC.

ViveBio, LLC is a privately held biotechnology company focused on providing cost-effective solutions for biological specimen transportation and storage. ViveBio’s mission is to expand access to healthcare and extend life through these cost effective solutions and other breakthrough technologies. The company’s initial focus has been to address the need for transporting plasma for quantitative HIV, Hepatitis C and Hepatitis B viral load and genotype tests. ViveBio’s manufacturing and corporate office is located in Alpharetta, Georgia.

December 5, 2013
PRESS RELEASE
ViveBio’s Transformational Specimen Storage and Transportation Device, ViveST™, Featured in Presentation at HEP DART 2013

Alpharetta, Georgia, December 5, 2013 - ViveBio, LLC announced today that ViveST™, its transformational specimen storage and transportation device, will be featured in a presentation at the 2013 HEP DART conference being held December 8-12, 2013 in Hawaii. The focus of HEP DART is to gather scientists and researchers to advance knowledge of ongoing drug development processes for Hepatitis B (HBV) and Hepatitis C (HCV). The presentation entitled, ViveST™ for HBV Testing: A Transformational Ambient Storage and Transportation Device, will be presented by Daniel McClernon, President and CSO of bioMONTR® Labs (Research Triangle Park, NC).

Infectious disease monitoring often requires collection sites to ship patient samples to reference laboratories, requiring careful temperature control and special packaging. In the study being presented, HBV positive plasma was loaded onto ViveST™, dried, capped and stored at room temperature. Results from all studies were compared to those from aliquots of frozen plasma. The HBV viral load from HBV positive plasma stored on ViveST™ at room temperature up to 60 days was identical to that of frozen plasma. A linear fit (R2 >0.99) was retained over the course of the 60-day study as indicated by linear regression analysis across all levels and all test points. This study demonstrates the utility of ViveST™ for transportation and storage of plasma, producing equivalent HBV viral load values with frozen plasma.

The key feature of the ViveST™ is a proprietary absorbent matrix onto which a biological specimen can be loaded by simple pipetting and allowed to dry. The dried sample can be easily reconstituted into a robust specimen that can be used in multiple downstream applications including RNA/DNA targets, cell recovery, and protein analysis.

ViveST™ is CE marked and has received ANVISA medical device registration in Brazil. For more information regarding ViveST™ and recent scientific publications and posters, please visit the ViveBio website at www.vivebio.com or contact Timothy Murray at murray@vivebio.com or Brad Nelson at nelson@vivebio.com or 877-814-7004.

Click Here to View the Poster

About ViveBio, LLC.

ViveBio, LLC is a privately held biotechnology company focused on providing cost-effective solutions for biological specimen transportation and storage. ViveBio’s mission is to expand access to healthcare and extend life through these cost effective solutions and other breakthrough technologies. The company’s initial focus has been to address the need for transporting plasma for quantitative HIV, Hepatitis C and Hepatitis B viral load and genotype tests. ViveBio’s manufacturing and corporate office is located in Alpharetta, Georgia.

November 18, 2013
ViveBio Appoints Timothy Murray President, ViveBio, LLC

ATLANTA, GA., November 18, 2013 – ViveBio, LLC a pioneer in biological specimen storage and transport technology today announced the appointment of Timothy Murray to the position of President.

"ViveBio is poised to expand access to healthcare and transform traditional logistics chains through use of our novel specimen storage and transport technologies," said Robert D. Cheeley, Chairman and CEO. "Tim brings a valuable combination of strategic planning, financial and operational expertise which will help us expand our product development and commercialization efforts. His 20 years of experience focusing on clinical research, molecular diagnostics and clinical laboratory businesses will be a tremendous asset to our organization,” said Mr. Cheeley.

Prior to joining ViveBio, Mr. Murray was the President & General Manager – North America of NorDiag, Inc. a publicly traded (OSE:NORD) molecular diagnostics company focused on automated systems for sample preparation. In May 2012, NorDiag was sold to DiaSorin, representing the fourth acquisition that Mr. Murray has been involved with.

"The ViveST technology will transform the way clinical specimens are collected, stored and transported. I am excited about leading ViveBio in the commercialization of this unique technology and look forward to driving the growth of the company," said Mr. Murray.

Mr. Murray is an inventor on U.S. and European method and design patents, as well as an author of peer-reviewed publications relating to clinical laboratory testing, stem cell research and infectious diseases diagnostics. Mr. Murray earned his BS in Biology/PreMed from Loyola University New Orleans.

November 17, 2013

The Naval Medical Research Center presented a poster entitled; Stability of IgG and Viral RNA in Dried Whole Blood in Commercially-Available RNA-Stabilization Products featuring ViveST&rade; at the American Society of Tropical Medicine and Hygiene annual meeting held November 13-17, 2013, in Washington, D.C.

Click Here to View the Poster

Their study used whole blood and compared multiple commercially-available RNA-stabilization products over a period of 4 weeks. They noted in their conclusions that “based on superior performance in stabilizing IgG and viral RNA” they will proceed with ViveST and one other product in studies involving clinical specimens.

November 7, 2013
PRESS RELEASE
ViveST™, a Transformational Specimen Storage and Transportation Device, Featured in Presentation at AMP 2013

Click Here to View the Poster

Alpharetta, Georgia, November 7, 2013 - ViveBio, LLC announced today that ViveST™, its transformational specimen storage and transportation device, will be featured in a presentation at the next annual meeting of the Association for Molecular Pathology (AMP) being held November 14-16, 2013 in Phoenix, Arizona. The presentation entitled, ViveST™: A Revolutionary Ambient Temperature Storage and Transportation Device for Utilization in Infectious Disease Testing, will be presented by Anita McClernon, Director of Laboratory Services for bioMONTR® Labs (Research Triangle Park, NC).

Infectious disease monitoring often requires collection sites to ship patient samples to reference laboratories, requiring careful temperature control and special packaging. In the study being presented, infectious plasma (HCV, HIV-1, or HBV) was loaded onto ViveST™, dried, capped and stored at room temperature. After recovery from ViveST™, specimens were analyzed using commercially available FDA approved viral load assays. These studies demonstrate ViveST™ utility for storing and transporting infectious plasma for subsequent analysis utilizing a range of viral targets (RNA and DNA). ViveST™ provides significant cost savings as compared to shipping samples on dry ice and can enhance access to healthcare globally while reducing the burden associated with shipping frozen samples.

The key feature of the ViveST™ is a proprietary absorbent matrix onto which a biological specimen can be loaded by simple pipetting and allowed to dry. The dried sample can be easily reconstituted into a robust specimen that can be used in multiple downstream applications including RNA/DNA targets, cell recovery, and protein analysis.

ViveST™ is CE marked and has received ANVISA medical device registration in Brazil. For more information regarding ViveST™ and recent scientific publications and posters, please visit the ViveBio website at www.vivebio.com or contact Richard Carroll, PhD, at carroll@vivebio.com or Brad Nelson at nelson@vivebio.com or 877-814-7004.

About ViveBio, LLC

ViveBio, LLC is a privately held biotechnology company focused on providing cost-effective solutions for biological specimen transportation and storage. ViveBio’s mission is to expand access to healthcare and extend life through these cost effective solutions and other breakthrough technologies. The company’s initial focus has been to address the need for transporting plasma for quantitative HIV, Hepatitis C and Hepatitis B viral load and genotype tests. ViveBio’s manufacturing and corporate office is located in Alpharetta, Georgia.

September 24, 2013
PRESS RELEASE
ViveBio’s Transformational Specimen Storage and Transportation Device, ViveST™, Featured in Presentation at ID Week.

Click Here to View the Poster

Alpharetta, Georgia, September 24, 2013 - ViveBio, LLC announced today that its transformational specimen storage and transportation device, ViveST™, will be featured in a presentation at the next annual meeting for the Infectious Disease Society of America being held October 2-6, 2013 in San Francisco, California. The presentation entitled, A Novel Ambient Storage and Transport Device for Utilization in Infectious Disease Testing: ViveST™, will be presented during the Global HIV Session on Saturday, October 5, 2013 by Daniel McClernon, President and CSO of bioMONTR Labs (Research Triangle Park, NC). In addition, the poster is included in a special presentation at the ID Week Global Health Gallery for investigators doing excellent work in Global Health.

Infectious disease monitoring often requires collection sites to ship patient samples to reference laboratories, requiring careful temperature control and special packaging. In this presentation, the data shows how ViveST™ offers an accurate and reproducible global solution that enhances access to healthcare and significantly reduces the burden associated with shipping frozen samples for quantitative and sequencing-based molecular diagnostic tests.

The key feature of the ViveST™ is a proprietary absorbent matrix onto which a biological specimen can be loaded by simple pipetting and allowed to dry. During the drying process, water in the biological sample is evaporated but biological analytes including proteins, virions and nucleic acids remain in the matrix. The dried sample can be easily reconstituted into a robust specimen that can be used in multiple downstream applications including RNA/DNA targets, cell recovery, and protein analysis.

ViveST™ is CE marked and has received ANVISA medical device registration in Brazil. For more information regarding ViveST™ and recent scientific publications and posters, please visit the ViveBio website at www.vivebio.com or contact Brad Nelson at nelson@vivebio.com or 877-814-7004.

About ViveBio, LLC

ViveBio, LLC is a privately held biotechnology company focused on providing cost-effective solutions for biological specimen transportation and storage. ViveBio’s mission is to expand access to healthcare and extend life through these cost effective solutions and other breakthrough technologies. The company’s initial focus has been to address the need for transporting plasma for quantitative HIV, Hepatitis C and Hepatitis B viral load and genotype tests. ViveBio’s manufacturing and corporate office is located in Alpharetta, Georgia.

August 12, 2013
PRESS RELEASE
ViveST™ was featured in a presentation at the 5th Annual Next Generation Dx Summit entitled, A Novel, 2nd Generation Device for Ambient Storage and Transportation for Downstream Infectious Disease Testing: ViveST™.

Download the Presentation Here.

August 12, 2013
PRESS RELEASE
ViveBio’s ViveST™ Specimen Storage and Transportation Device Featured in Presentation at 5th Annual Next Generation Dx Summit

Alpharetta, Georgia, August 12, 2013 - ViveBio, LLC announced today that its specimen storage and transportation device, ViveST™, will be featured in a presentation at the 5th Annual Next Generation Dx Summit being held August 20-22, 2013, in Washington, DC. The presentation entitled, A Novel, 2nd Generation Device for Ambient Storage and Transportation for Downstream Infectious Disease Testing: &ViveST; trade will be presented Thursday, August 22, 2013 at 4:05 pm.

Infectious disease monitoring often requires collection sites to ship patient samples to reference laboratories, requiring careful temperature control and special packaging. In this presentation, data evaluating the stability and quantitative reproducibility of infectious plasma specimens stored on ViveST™ and analyzed with quantitative RT-PCR and genotyping sequencing technologies will be presented. The data shows how ViveST™ can offer an accurate and reproducible global solution that enhances access to healthcare and significantly reduces the burden associated with shipping frozen samples for quantitative and sequencing-based molecular diagnostic tests.

The key feature of the ViveST™ is a proprietary absorbent matrix onto which a biological specimen can be loaded by simple pipetting and allowed to dry. During the drying process, water in the biological sample is evaporated but biological analytes including proteins, virions and nucleic acids remain in the matrix. The dried sample can be easily reconstituted into a robust specimen that can be used in multiple downstream applications including RNA/DNA targets, cell recovery, and protein analysis, allowing for use with such tests as viral load quantification, viral genotyping and sequencing.

ViveST™ is CE marked and has received ANVISA medical device registration in Brazil. For more information regarding ViveST™ and recent scientific publications and posters, please visit the ViveBio website at www.vivebio.com or contact Brad Nelson at nelson@vivebio.com or 877-814-7004.

Download the PDF Here.

About ViveBio, LLC

ViveBio, LLC is a privately held biotechnology company focused on providing cost-effective solutions for biological specimen transportation and storage. ViveBio’s mission is to expand access to healthcare and extend life through these cost effective solutions and other breakthrough technologies. The company’s initial focus has been to address the need for transporting plasma for HIV, Hepatitis C and Hepatitis B viral load and genotype tests. ViveBio’s manufacturing and corporate office is located in Alpharetta, Georgia.

June 26, 2013
PRESS RELEASE
ViveBio Introduces Next-Generation ViveST™ Matrix to Expand Healthcare Access and Lower Specimen Transportation Costs

Alpharetta, Georgia, June 26, 2013 - ViveBio, LLC announced today the introduction of its next-generation ViveST™ proprietary matrix for the storage and transportation of biological specimens, expanding sample collection to remote areas and lowering specimen transportation costs. With the new matrix, the dried sample can be easily reconstituted into a robust specimen that can be used in multiple downstream applications including RNA/DNA targets, cell recovery, and protein analysis allowing for use with such tests as viral load quantification, genotyping and sequencing.

ViveST™ is a high volume, dried specimen storage and transportation system that allows the specimen to be handled without refrigeration. The device is intended to be used for biological specimens as an alternative to frozen plasma or dried blood spots. The benefits of ViveST™ include:

  • Ambient transport and storage of specimens eliminating the time and cost of preparing and shipping frozen samples
  • Easy to use workflow with rapid turnaround time
  • High sample volume of 1.0-1.5 mL that is often required for testing

The key feature of the ViveST™ is a proprietary absorbent matrix on which a biological specimen can be loaded by simple pipetting and allowed to dry. During the drying process, water in the biological sample is evaporated but biological analytes including proteins, virions and nucleic acids remain in the matrix.

ViveST™ is CE marked and has received ANVISA medical device registration in Brazil. Performance data using this next-generation matrix was recently presented at the International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies held June 4-8, 2013 in Toronto, Canada and the 29th Clinical Virology Symposium held April 28-May 1, 2013 in Daytona Beach, Florida. For more information regarding ViveST™ and recent scientific publications and posters, please visit the ViveBio website at www.vivebio.com or contact Brad Nelson at nelson@vivebio.com or 877-814-7004.

Download the PDF Here.

About ViveBio, LLC

ViveBio, LLC is a privately held biotechnology company focused on providing cost-effective solutions for biological specimen transportation and storage. ViveBio’s mission is to expand access to healthcare and extend life through these cost effective solutions and other breakthrough technologies. The company’s initial focus has been to address the need for transporting plasma for HIV, Hepatitis C and Hepatitis B viral load and genotype tests. ViveBio’s manufacturing and corporate office is located in Alpharetta, Georgia.

June 8, 2013
A Poster Featuring ViveST™ Presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, June 4-8, 2013, Toronto, Canada.

A poster featuring ViveST™ was presented by Daniel McClernon of bioMONTR®, an independent research laboratory located in Research Triangle Park, North Carolina, during the International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies held June 4-8, 2013 in Toronto, Canada. The poster entitled A Novel Ambient Storage and Transport Device for Utilization in Infectious Disease Testing:ViveST™, evaluated the performance of ViveST as a storage and transport device for use with viral load and drug resistance assays. View the poster Here.

May 1, 2013
Two Posters Featuring ViveST™ Presented at 29th Clinical Virology Symposium, April 28-May 1, 2013, Daytona Beach, Florida.

Two posters featuring ViveST™ were presented by Daniel and Anita McClernon of bioMONTR®, an independent research laboratory located in Research Triangle Park, North Carolina, during the 29 Virology Symposium held April 28 - May 1, 2013 in Daytona Beach, Florida. A poster entitled Real-Time Stability of Plasma Using ViveST™, a Revolutionary Ambient Temperature Storage and Transportation Device, evaluated the stability of infectious plasma samples stored on ViveST™ and analyzed with the Abbott RealTime HCV and HIV-1 viral load assays - View Poster. A second poster entitled Evaluation of ViveST™ Using the COBAS TaqMan HCV Test v2.0, evaluated the performance of COBAS® TaqMan® HCV Test, v2.0 when using HCV infected samples stored and processed on ViveST® - View Poster.

December 4-7, 2012
Poster Featuring ViveST™ Presented at HIV DART 2012, Frontiers in Drug Development for Antiretroviral Therapies

A poster entitled Cost Comparison of Shipping Frozen Plasma Versus Ambient Temperature Using ViveST™ was presented at the HIV DART 2012 conference held December 4-7, 2012 in San Diego, California. The poster, presented by Daniel McClernon, summarizes a study conducted by bioMONTR®, a research laboratory located in Research Triangle Park, NC. The purpose of the study was to assess the cost savings of sample transport and storage in order to mediate the costs of healthcare. This study compared the cost of shipping frozen plasma to the cost of shipping plasma at ambient temperature using ViveST. The results for this study show that there was an average per sample cost savings of 77% for shipments of ViveST samples compared to frozen plasma. This study confirms that ambient temperature shipments utilizing the ViveST sample transportation and storage device provide significant cost savings compared to shipping frozen samples on dry ice. Click here to view the poster.

December 3, 2012
MedCity News Blood Storage and Transport Article

An article featuring ViveBio was published by MedCity News on December 3, 2012. The article entitled, Blood storage and transport startup puts focus on growing hepatitis C testing market, highlights ViveBio’s recent fund raising success and its strategic focus on the growing hepatitis C market. Click here to view the article or you can go directly to the MedCity News website at http://medcitynews.com/?s=vivebio.

October 25th - 27th, 2012
Poster Featuring ViveST™ Presented at Association for Molecular Pathology (AMP) Annual Conference 2012

A poster entitled HCV and HIV Testing Using a Novel Dried Ambient Sample Collection and Transport Device, ViveST comparing the performance of ViveST, a novel ambient transportation matrix, to frozen plasma for use with commercially available HCV and HIV-1 viral load and genotypic assays was presented at this year’s AMP Annual Meeting held October 25 - 27, 2012 held in Long Beach, CA. The poster, presented by Anita McClernon, summarizes studies conducted by bioMONTR, a research laboratory located in Research Triangle Park, NC. The studies conclude that plasma recovered from ViveST yielded comparable results to frozen plasma for sequence analysis of viral RNA and that plasma recovered from ViveST is viable for use in Abbott RealTime and ViroSeq Drug Resistance Assays without requiring additional processing. Further, bioMONTR studies conclude that the use of ViveST can enhance access to viral load and genotypic testing in resource-limited countries and reduce the burden associated with shipping frozen samples. Click here to view the poster.

October 15th, 2012
New ViveBio Paper Published in October 2012 Journal of Clinical Virology

A recent paper, Barr KL, et al. Recovery of live virus after storage of at ambient temperature using ViveST™. J Clin Virol (2012), was published in the October 2012 edition of the Journal of Clinical Virology. A major impediment to performing virological field studies in developing nations is the lack of ultra-low freezers as well as the expense and difficulty of shipping frozen samples. A commercially available product, ViveST™, was developed to preserve nucleic acids at ambient temperature for use in specimen storage and transportation. However, its applications as a viral storage, transport and recovery device have not been evaluated. This study was designed to examine the ability of ViveST™ to preserve live virus following storage at ambient temperature. The publication text and results can be found at: http://dx.doi.org/10.1016/j.jcv.2012.09.005